Which country and company developed and produced larotrectinib?

Larotrectinib is a new anti-cancer drug developed and produced by the American pharmaceutical company Loxo Oncology (now a subsidiary of Eli Lilly and Company). Loxo Oncology is a biopharmaceutical company focused on targeted cancer treatments. Its mission is to provide patients with more effective treatment options through innovative drug research and development.

Larotinib is a drug that targets tumors with NTRK (neuronal growth factor receptor kinase) gene fusion. NTRKGene fusion is a rare but genetic abnormality found in a variety of cancers, including soft tissue sarcoma, infantile fibroma, lung cancer, and more. Loxo OncologyThrough in-depth research on the mechanism of NTRK gene fusion, it successfully developed larotrectinib and became one of the leaders in this field.

During the development process, larotrectinib went through clinical trials, and the results showed that it achieved significant anti-tumor effects in patients carryingNTRK gene fusions. This enabled larotrectinib to be approved by the U.S. Food and Drug Administration (FDA) and obtain marketing authorization in multiple countries, making it a highly anticipated innovative drug worldwide.

Larotrectinib has been launched in China and has not yet been included in medical insurance. Since it has not been launched in China for a long time, it may be difficult to purchase it in hospitals. For specific conditions, it is recommended to consult the local hospital pharmacy. In foreign markets, larotinib has two options: original drug and generic drug. Original drugs include the German version, the American version, the European version and the Hong Kong version, and the price is about 10,000 to 20,000 yuan. In comparison, generic drugs are much cheaper. There are Lao and Bangladeshi versions of generic drugs, and the price is around two to three thousand. It is worth noting that the ingredients of original drugs and generic drugs are basically the same.